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Abstract
Purpose—Rectal cancer is often clinically resistant to radiotherapy and there would be value to
identifying molecular markers to define the biological basis for this phenomenon. NF-κB is a
potentially anti-apoptotic transcription factor that has been associated with resistance to
radiotherapy in model systems. This study was designed to evaluate NF- κB activation in rectal
cancers being treated with chemoradiation to determine whether NF- κB activity correlates with
outcome in rectal cancer
Methods and Materials—22 patients were biopsied at multiple time points in a prospective
study, and another 50 were analyzed retrospectively. Pre-treatment tumor tissue was analyzed for
multiple NF- κB subunits by immunohistochemistry (IHC). Serial tumor biopsies were analyzed
for NF- κB-regulated gene expression by RT-PCR and for NF-κB subunit nuclear localization by
IHC.
Results—Several NF- κB target genes (Bcl-2, cIAP-2, IL-8 and TRAF1) were significantly
upregulated by a single fraction of radiotherapy at 24 hours demonstrating for the first time that
NF-κB is activated by radiotherapy in human rectal tumors. Baseline NF-κB p50 nuclear
expression did not correlate with pathologic response to radiotherapy, but increasing baseline p50
was prognostic for overall survival (HR 2.15, p = 0.040).
Conclusions—NF-κB nuclear expression at baseline in rectal cancer is prognostic for overall
survival but not predictive of response to radiotherapy. Larger patient numbers would be needed to
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assess the effect of NF-κB target gene upregulation on response to RT. Our results suggest that
NF-κB may play an important role in tumor metastasis as opposed to resistance to
chemoradiotherapy.
Introduction
Rectal cancer is common, representing nearly a third of colorectal cancers, and
approximately 40% of rectal cancer patients die from their disease 1. Despite improvement
in surgical techniques local control remains a problem with surgery alone, and current
combined modality therapy is still inadequate for many patients with locally advanced
tumors 2. Radiation and chemotherapy are used to minimize the chance of local recurrence
after successful surgery, and to permit sphincter-sparing surgery for low-lying cancers that
may otherwise require abdominoperineal resection. Standard radio-chemotherapy with 5-FU
results in pathologic complete remission (pCR) only 8%–20% of the time 3, 4; our current
understanding of the molecular basis for the relative resistance to radiation of the majority of
adenocarcinomas is incomplete.
Evidence of survival pathway activation by radiation has been demonstrated via global gene
expression profiling in solid tumor cell lines after single therapeutic-dose fractions of
ionizing radiation 5–7. In theory, survival mechanisms may not be detectable if assayed in a
tumor at baseline, but rather are activated by stress such as radiotherapy-induced DNA
damage.
One such cell survival mechanism involves NF-κB, a transcription factor composed of
heterodimers of a family of DNA-binding proteins that has been shown to suppress
apoptosis. There are 5 characterized members of the family: p65/RelA, c-Rel, p50, p52 and
RelB8. The most intensively studied form of NF-κB is the heterodimer composed of the p50
and p65 subunits. NF-κB exists in the cytoplasm in an inactive form maintained by binding
to repressor proteins known as I-kappa B (IκB) proteins. In response to a wide variety of
stimuli including TNF, DNA-damaging agents, and ionizing radiation, IκB proteins are
phosphorylated, ubiquitinated, and degraded by the ubiquitin-proteasome pathway. Loss of
IκB frees NF-κB to enter the cell nucleus where NF-κB acts as a transcriptional activator of
a variety of genes encoding proteins involved in immunity, inflammation, cell proliferation,
and protection from apoptosis in the case of many cancer cells. The ability of NF-κB to
suppress apoptosis occurs at least partly through the transcriptional upregulation of genes
encoding proteins that block apoptosis via several mechanisms9, 10. As an example, in an
unbiased screen of genes expressed after radiation exposure in CLL cells, cellular inhibitor
of apoptosis protein (c-IAP) mRNA was found to be strongly upregulated11 after radiation
exposure.
There are data suggesting that NF-κB activation by radiation contributes to radioresistance.
In a radioresistant breast cancer model, gene array experiments performed to identify
expression changes associated with radioresistance demonstrated increased expression of
NF-κB -regulated genes in radioresistant cells compared to parental radiosensitive cells 12.
There is also preclinical evidence that constitutive NF-κB activation could influence
radiation response. One group demonstrated that high basal NF-κB activity negatively
correlates with basal apoptosis of head and neck cancer cell lines, as well as with
radiosensitivity13. NF-κB induction by radiation is anti-apoptotic in an array of colorectal
cancer cell lines and in a colorectal xenograft model. Furthermore, inhibition of radiation-
induced NF-κB induction increases apoptosis as measured by both in vitro and in vivo
assays14.
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In contrast to the idea of treatment-induced NF-κB activation, NF-κB nuclear localization
indicative of activation has been described at baseline in tissue samples from untreated
colorectal cancers, pancreatic, breast, and head and neck cancers, suggesting that
constitutive NF-κB activation occurs in a fraction of cancers of many types15–17. In the
largest series of human colorectal tumors studied to date, 31% of tumors exhibited activation
of NF-κB as measured by detection of nuclear p65/RelA18. These findings lead to questions
of which mechanisms are more important for determination of clinical behavior of a cancer;
inducible activation or constitutive activation of NF-κB. To clarify these mechanisms we
wished to address the following questions in a population of patients receiving preoperative
radiotherapy for rectal cancer:
1. Whether rectal tumors that demonstrate baseline NF-κB activation are less likely to
respond clinically to radiation therapy
2. Whether changes in NF-κB activation status are induced by a single fraction of
radiotherapy
3. Whether radiation-induced activation of NF-κB can be measured in vivo, and if so
whether such changes occur differentially in radiotherapy responders and non-
responders.
In order to address these questions we designed a study in which serial biopsies were taken
during standard fluorouracil-based pre-operative chemoradiation. These biopsies were
assayed for multiple aspects of NF-κB activity, and results correlated with pathologic
response assessed at the time of surgery.
Methods and Materials
Patients
Two patient cohorts were utilized for this study; the first was a group of patients
prospectively enrolled to a biopsy protocol that is described below. The second cohort was a
sequential, retrospective cohort of patients who underwent preoperative chemoradiation and
surgery at our institution.
Cohort 1 Protocol eligibility
Eligible patients had clinically staged T3-4N0 or T2-4N1-2, pathologically-documented
adenocarcinoma of the rectum who were thought by the treating team to be fit for
preoperative chemoradiotherapy. All patients were staged using endoscopic ultrasonography
and CT or MRI of the abdomen and pelvis.
Cohort 2 eligibility. A group of patients treated at UNC Hospitals with preoperative
chemoradiation therapy for rectal cancer to the same doses and radiation fields was
identified from our institutional Tumor Registry. Criteria for selection included availability
of a pre-operative biopsy suitable for immunhistochemical analysis and surgery performed
at UNC. This consisted of 49 patients.
Both portions of the study were approved by our Institutional Review Board and we
followed all standard procedures for protection of human research subjects.
Treatment
Patients were treated with standard pelvic radiotherapy to 45 Gy with a 5.4 Gy boost
beginning on day one in 180cGy fractions. Concurrent continuous infusion 5-fluorouracil-
based chemotherapy began on day 2 after the final biopsy was performed. Biopsies were
obtained using a rigid sigmoidoscopy and alligator forceps at three time points: 1) prior to
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initiation of treatment (at the time of planned endoscopic ultrasonography), 2) 2, 4 or 6
hours after the first fraction of radiation therapy and 3) 24 hours after the first fraction of
radiation therapy. Six biopsies were collected at each time, half of the samples were frozen
immediately in liquid nitrogen, the other half preserved in formalin for paraffin embedding.
Dose modification and treatment delays were performed per standard of care. All patients
who were candidates for surgery underwent resection of their rectal tumors four to eight
weeks after the end of radiation therapy.
Clinical Endpoints
The primary clinical outcome measure for this study was pathologic response, which was
divided into three categories for purposes of data analysis: limited response (NR: gross
disease present), major response (MR: only microscopically visible disease remaining) or
complete response (CR: no evidence of residual tumor cells pathologically). AJCC
pathologic stage at surgery was also assessed.
Molecular Endpoints
Immunohistochemical (IHC) analysis—For patients 1–24 (prospective study cohort)
tissue microarrays (TMA) were constructed from the biopsies using previously described
methods 19. Forty-nine additional patients were identified retrospectively. For these
patients, sections were taken from whole archived biopsy tissues. Samples were blocked for
endogenous peroxidase activity with hydrogen peroxide. Antigen recovery was done by
steaming of slides for 25 min in DakoCytomation Target Retrieval Solution (S1699
DakoCytomation, Inc. Carpinteria, CA 93013) for each primary antibody utilized. Sections
were then exposed to the primary antibodies (table 1) for 30 min. at room temperature,
rinsed in Dako wash buffer (S3006 DakoCytomation, Inc. Carpinteria, CA 93013),
incubated with the Dako LSAB2 kit according to the manufacturer’s instructions for 10 min
at room temperature (K0675, DakoCytomation, Inc. Carpinteria, CA 93013). Detection of
the antibody/antigen complex was visualized using 3–3 diaminobenzidine for 5 min (K3468
DakoCytomation, Inc. Carpinteria, CA 93013). Slides were then rinsed in water, lightly
counterstained in filtered Mayer’s hematoxylin (S3309 DakoCytomation, Inc. Carpinteria,
CA 93013), rinsed, dehydrated, cleared, and mounted.
Scoring of Tissue Microarrays—Individual TMA cores were scored visually and semi-
quantitatively by the study pathologist (WKF) who was blinded to all relevant patient
clinical and pathologic data. The intensity “score” included measure of signal strength (0–
3+) multiplied by percentage of cells of interest showing nuclear immunoreactivity (decade
increments, 0–100%). Where possible, two separate biopsies were processed for each patient
at each time point to minimize the possibility that localized differences in gene expression
might affect results. For NF-κB subunits, nuclear translocation occurs after activation, so
increases in nuclear staining are an acceptable surrogate for NF-κB activation.
Quantitative fluourescence RT-PCR
Total RNA was isolated from single frozen biopsy samples using an RNeasy kit (Qiagen,
cat. #74104). DNA contamination was resolved by treating all total RNA isolates with
DNase I RNase free (Ambion, cat #AM2222). Samples were diluted to 2ng/ul and 5ul/
reaction was used. Samples were run in triplicate.
Applied Biosystem’s Primer Express software was used to design primers for the following
genes: Bcl-2, Bcl-xL, cIAP1, cIAP2, TRAF1, TRAF2, IκBα, IKKε, IL-8, and cyclin D1
(primers Biosearch Technologies cat. # RPH-5). Probes (Biosearch Technologies cat.
#DLO-FB1-5) were labeled with 5’FAM-3’BHQ-1. One step RT-PCR was performed (40
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cycles). Values for relative mRNA expression were derived by calculating the mean cycle
number, normalizing by subtracting 40 from the mean (40 = the maximum # of cycles) then
calculating en where n is the normalized cycle number value.
Statistical Methods—The study was initially designed to accrue 60 patients
prospectively. This was eventually limited by slow accrual, likely because of the
requirement for multiple biopsies. The initial sample size calculation was based on the
primary objective for estimating the probability of activation of NF-κB and of testing for
independence between NF-κB activation and therapeutic outcome as follows: The
probability of activation of NF-κB will be estimated as a binomial proportion. An exact
binomial 95% confidence interval based on n=60 patients has a maximum width of 0.13 on
either side of the point estimate, with the interval being widest when 50% of the patients
show activation. For example, if 6/60 patients show activation, the confidence interval will
be (0.038, 0.21), if 12/60 activate it will be (0.11, 0.33), if 18/60 activate it will be (0.19,
0.43) and if 30/60 activate it will be (0.37, 0.63). The final N was based on availability of
prospectively accrued patients and on availability of archived tumor biopsies at our
institution.
For analysis, the natural log transformation of the gene scores was the most appropriate for
these data; thus, results are reported in terms of a fold difference. Generalized estimating
equations, which account for correlated data, were used to estimate the differences in gene
scores and NF-κB subunits at different time points. To compare changes in gene scores
among the three pathologic response groups (NR, MR, CR), Kruskal-Wallis tests were
performed, and nominal p-values are reported; additionally, the NR and MR pathologic
response groups were combined and compared to the CR group, using Wilcoxon Rank-Sum
tests. The Kruskal-Wallis and Wilcoxon Rank Sum tests were also used to compare the NF-
κB subunit expression at baseline among the pathologic response groups for the larger
sample of 72 patients. Survival curves were constructed using the Kaplan-Meier method,
and Cox regression models were fit to see if the NF-κB subunits were significantly
associated with overall survival. Statistical analyses were performed with SAS statistical
software (SAS Institute Inc, Cary, NC) and R software (http://www.r-project.org/).
Results
Evidence of NF-κB activation by a single fraction of RT can be visualized by RT-PCR for
NF-κB target genes
Twenty-five patients were enrolled to the prospective biopsy collection study. Of these, 24
were successfully biopsied. Two patients’ tumors yielded poor quality RNA. Thus, 22
patients’ tumor samples were assayed by RT-PCR. Eleven genes known to be transcriptional
targets of activated p50/p65 were evaluated (inhibitors of apoptosis Bcl-2, Bcl-xL, cellular
inhibitor of apoptosis protein [cIAP]1, cIAP2, Tumor necrosis factor receptor-associated
factor [TRAF]1, TRAF2, the NF-κB regulated cytokine interleukin-8 [IL-8], the cell-cycle
regulator cyclin D1, and regulators of NF-κB activation I-kappa kinase (IKK)ε, IκBα).
No significant differences in expression were noted for any of the genes between the
baseline and 2–6 hour time points. At 24 hours, statistically significant increases in gene
expression were noted for 4 of the 11 NF-κB-regulated genes (table 2). For two of the genes
(IL-8, TRAF1), the difference between 2–6 hour gene expression and 24 hour gene
expression was also significant, supporting the assertion that these observations were not
made by chance. The general trend was for increased expression of all 11 genes, even where
statistical significance was not met with a range of 1.03 fold increase to a 7.44 fold increase
between 0 and 24 hours. None of the genes studied decreased in expression on average, but
they did decrease in individual patients (Data not shown).
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Among the 22 patients assayed by RT-PCR, 4 had a pathologic CR, 8 had microscopic
residual disease (major response) and 10 had gross residual disease (considered non-
response for this analysis). Given the small sample size for each pathologic response group,
we were unable to demonstrate any association between specific NF-κB target gene
expression and pathologic outcome. The difference in gene expression between biopsies
obtained 4 and 24 hours after RT was statistically significant for cIAP2 when the CR group
was compared to the MR and NR groups combined (p=0.048), and there was a similar trend
for IKK_epsilon (p=0.06). When comparing all three groups separately, a borderline
significant difference was found for cyclin D1 from T0 to T24 (p=0.07). Baseline gene
expression values were not predictive of pathologic response nor were any predictive of
overall survival.
Use of IHC for NF-κB nuclear localization is insufficient to observe changes in NF-κB
activation status by a single fraction of RT
As a second method to assess whether NF-κB activation occurs as a result of a single
fraction of RT, we utilized IHC for NF-κB activation, as defined by nuclear localization of
several well-studied NF-κB subunits (p50, p65 and p52). Samples for 15 of the 24
prospectively enrolled (multiple biopsy) patients were evaluable by IHC for at least two
timepoints. Sample dropout occurred primarily due to lost or uninformative (for example
only adenoma seen in a given core) spots on the TMA, which occurred in spite of having as
many as 6 cores placed on the TMA for each time-point sample. Based on this sample of 15
patients, we were unable to demonstrate significant changes in nuclear NF-κB expression at
either the early (2–6 hour) or 24-hour time-point compared to baseline, suggesting that IHC
is insufficiently sensitive to demonstrate acute changes in NF-κB activation status resultant
from radiotherapy.
Baseline NF-κB status as measured by IHC is prognostic for OS, but does not predict
response to radiotherapy
In order to increase our patient numbers for selected end-points, we chose to study NF-κB
baseline expression retrospectively in 49 additional patients who had pre-treatment biopsy
tissue available in our pathology archives and who were treated with the same standard
chemoradiotherapy followed by surgery. These samples were combined with those of the
patients who had pre-treatment biopsies for the prospective component of the study.
Demographics and response percentages for the entire group are shown in table 3. The entire
group of 72 patients demonstrated overall survivals similar to historically reported figures
based on pathologic stage and response to radiotherapy (Figure 1)
The majority of cases were positive (nuclear) to some extent for both p50 (58/63, 92%) and
p65 (49/61, 80/%) based on a cutoff of 100 points, approximating a 1+ average staining
intensity. P52 subunit positivity was less frequent, with many samples displaying minimal
(0–10 point) staining (38/64, 59%) and 31/64 (48%) displaying high (100 or greater)
intensity nuclear staining.
There was no association between nuclear staining for any of the 3 studied NF-κB subunits
and pathologic response to radiotherapy (CR vs. micro residual versus gross residual- table
4), refuting a primary hypothesis of our study.
There was however, a significant association between p50 nuclear expression (above or
below the median of 180 units) and overall survival (HR 2.15, p = 0.040) (figure 2) with
high levels of nuclear expression associated with a poor prognosis There was a similar trend
for p65 (HR 1.5, p = 0.28), but this did not demonstrate statistical significance. There was no
apparent association between baseline p52 nuclear expression and survival.
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There has been increasing interest in defining molecular markers of radiation response or
resistance and long-term outcome for patients with solid tumors such as rectal cancer. A
number of studies have attempted to provide guidance in this determination. Unfortunately,
many of these studies have used tissue samples obtained at the time of surgical resection,
after the delivery of the radiation therapy. This approach is suboptimal, as molecular
changes produced by the radiation therapy itself may significantly affect the analysis.
Additionally, tissue samples obtained after a course of radiation therapy are lacking the
population of cells that have been killed by the radiation therapy, and this may represent the
population of cells of most interest.
There is a large body of information demonstrating that insults to a cell will impact gene
expression patterns, particularly by inducing expression of cellular damage response genes
such as those regulated by NF- κB. Radiation represents such an insult, and it is has
previously been demonstrated that cancer cells facilitate repair of injury induced by a
radiation exposure by the transcription of a large number of genes aimed at repair and
survival20–22. It is likely that even a single dose of radiation, as is delivered clinically
during an extended 5–6 week course of therapy, could influence the gene expression pattern
in a major way. Thus, the gene expression profile of a cell before the initiation of a radiation
course may not be relevant to predicting the response of the tumor during the course of
radiation therapy.
In order to better define these issues as it relates to rectal cancer, we initiated a clinical trial
in a group of patients with rectal cancers that required pelvic radiation therapy combined
with concurrent 5-fluorouracil chemotherapy. We obtained biopsies for
immunohistochemistry and RT-PCR at three points: before the initiation of treatment, 2–6
hours after the first dose of radiation therapy and 24 hours after the first dose of radiation
therapy. No significant changes in expression of NF- κB -related genes were seen at any
early time-point (2–6 hours) suggesting that some time between 6 hours and 24 hours (or
perhaps more) is optimal to assess gene expression changes in this setting.
We initially hoped to correlate information on gene expression changes with outcome as
measured by pathological complete response, or near pathological complete responses. We
are not aware of this type of study having ever been done before specifically evaluating
radiation response or the NF-κB pathway. Debucquoy23 recently reported on 41 rectal
cancer patients in whom biopsies were obtained before and after the administration of
cetuximab. They found that cetuximab exposure down-regulated genes involved in
proliferation and invasion and up-regulated inflammatory gene expression. This is the only
other study, to our knowledge, where gene expression was evaluated during therapy in rectal
cancer patients to determine the effect of a therapeutic intervention. Given the numbers of
patients we were able to accrue to our prospective study, we were not able to achieve the
goal of demonstrating that NF- κB -related gene induction per se was correlated with
radiation response.
Our group previously performed studies that suggested the importance of the NF-κB
pathway in colorectal cancer response to radiotherapy. In-vitro and in-vivo animal studies by
Russo et al.14 demonstrated that NF- κB was induced by radiotherapy, that this induction
led to poor response, and that abrogation of NF- κB induction by several means could lead
to radiosensitization. We thus designed the present study to emphasize evaluation of the NF-
κB pathway, and selectively measured portions of this pathway to correlate with the clinical
end-points as well as other genes that were relevant to that pathway.
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Eleven genes known to be transcriptional targets of activated p50/p65 were evaluated
(inhibitors of apoptosis Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein [cIAP]1,
cIAP2, Tumor necrosis factor receptor-associated factor [TRAF]1, TRAF2, the NF- κB
regulated cytokine interleukin-8 [IL-8], the cell-cycle regulator cyclin D1, and regulators of
NF- κB activation IKKε, IκBα). Four genes were shown to increase significantly after
radiotherapy in our study including Bcl-2, cIAP-2, IL-8 and TRAF1; these showed 1.7–7.4
fold increases over baseline 24 hours after a single dose of irradiation. Bcl-2, cIAP-2 and
TRAF1 are all well-described inhibitors of apoptosis. Upregulation of these genes supports
the general idea that radiation induces NF- κB in spite of the fact that we could not
demonstrate this directly utilizing the relatively crude method of immunohistochemistry.
Although studies of this type are difficult to perform, we were able to demonstrate the
feasibility of obtaining the necessary biopsies. This required coordination between the study
team, and a dedicated team of surgeons and radiation oncologists. Presumably because of
the difficulty of this protocol for patients, we were not able to accrue the originally desired
number of patients, and therefore added to the study an additional group of patients who
were previously treated and had pre-treatment tumor tissue available to look at constitutive
NF- κB expression at baseline. This turned out to be fruitful, as NF- κB p50 was in fact a
prognostic factor for overall survival, but not a predictive factor for response to
radiotherapy.
Previous studies have demonstrated the importance of NF-κB in advanced colorectal cancer
outcomes, and these data are consistent with those studies. In fact, a study by Scartozzi et al.
24 suggests NF- κB expression as a predictive factor of response to a combination of
irinotecan and cetuximab. Our data suggest that NF- κB may simply be prognostic given that
our patients were treated only with 5-FU based adjuvant therapy. These conclusions are
limited by relatively small numbers, and analysis of a larger dataset is planned.
Our data also suggest that all NF-κB subunits are not equal, and that some may be
prognostic while others are not. The lack of correlation between the prognostic marker and
the pathological response to preoperative radiation therapy with concurrent chemotherapy
may suggest that NF-κB impacts on survival via promotion of the metastatic process and
perhaps alters chemotherapy sensitivity rather than by affecting radiation therapy sensitivity
primarily.
Lastly, when measuring expression of specific NF-κB-regulated genes, we were clearly able
to demonstrate the induction of a subset of genes by a single dose of 180 cGy of radiation
therapy. This change was seen only at the 24 hour time-point, and not at 2, 4 or 6 hours,
giving some indication of the time course of these changes. The magnitude of these changes
were such that they could potentially affect the response to the radiation course, although we
were not able to demonstrate that given the small number of patients. Direct changes in
nuclear NF- κB localization were not, however, large enough that they could be measured
by immunohistochemistry. This has implications for how studies of this type are conducted.
Assay sensitivity is an important issue, and an erroneous answer due to poor test sensitivity
can impact on our understanding of the biology of tumor response to therapy.
SUMMARY
The reasons for cellular sensitivity to radiation therapy and chemotherapy are complex. Part
of that complexity is due to the fact that the use of radiation therapy can induce gene
expression that can then alter the response of the tumor to the therapeutic intervention. We
have demonstrated, to our knowledge for the first time in patients, that such gene expression
change does indeed occur and that the altered expression varies between molecular markers
and that the changes do not reflect global up or down gene expression changes. We have
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also demonstrated that the NF-κB pathway is important in the long-term survival of rectal
cancer patients, and that this is likely independent of radiation effect. Further studies of
molecular markers of response may need to consider not only the baseline status of those
markers, but also their status after the initiation of therapy. We have continued to obtain
fresh-frozen biopsies of tumors preoperatively, and our future efforts will be aimed at
discovery using both microarray and high-throughput sequencing techniques to try and
identify novel, potentially targetable predictors of radiotherapy response.
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Kaplan-Meier curves for overall survival by stage (A) and pathologic response to
radiotherapy (B)
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Kaplan-Meier curve for overall survival by p50 nuclear staining above or below median
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Table 2
NF-κB target gene expression differences from baseline
Fold Increase (95% CI) p-value
Bcl-2 Baseline to 24hrs 3.68 (1.429, 9.479) 0.007
cIAP-2 Baseline to 24hrs 1.78 (1.029, 3.089) 0.039
IL-8 Baseline to 24hrs 7.44 (1.576, 35.135) 0.01
2–6 hrs to 24hrs 11.61 (3.759, 35.848) <0.0001
TRAF1 Baseline to 24hrs 1.67 (1.057, 2.733) 0.029
2–6 hrs to 24hrs 2.12 (1.275, 3.537) 0.004
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Table 3
Patient demographics
Age 58 (range: 26, 89)
Sex
  Male 43 (60%)
  Female 29 (40%)
Race
  White 53 (75%)
  Black 16 (22%)
  Other 2 (3%)
Stage
  II 23 (34%)
  III 37 (54%)
  IV 8 (12%)
Pathologic Stage
  Gross Residual 46 (64%)
  Microscopic 14 (19%)
  Pathologic CR 12 (17%)
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Table 4
Baseline NF-κB subunit expression versus response to therapy
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